Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Myelodysplastic Syndromes 77Leukemia, Myeloid, Acute 72Leukemia, Myelogenous, Chronic, BCR-ABL Positive 34Myeloproliferative Disorders 33Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Lymphoma, Non-Hodgkin 21Primary Myelofibrosis 18Leukemia, Myelomonocytic, Chronic 17Hodgkin Disease 15Leukemia 14Myelodysplastic-Myeloproliferative Diseases 12Polycythemia Vera 10Leukemia, Biphenotypic, Acute 10Histiocytosis, Langerhans-Cell 10Anemia, Refractory, with Excess of Blasts 10Sarcoma 9Neuroblastoma 9Multiple Myeloma 9Leukemia, Lymphocytic, Chronic, B-Cell 9Glioma 9Wilms Tumor 8Rhabdoid Tumor 8Neuroectodermal Tumors, Primitive, Peripheral 8Medulloblastoma 8Hepatoblastoma 8Ependymoma 8Blast Crisis 8Thrombocythemia, Essential 7Rhabdomyosarcoma 7Osteosarcoma 7

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphangioleiomyomatosis × Myeloid × 30 days × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡